Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • Leadership
    • Team
    • Publications
    • Careers
  • Diseases/Disorders
    • One Brain
    • ALS
    • Alzheimer’s
    • Autism
    • Brain Cancer
    • Brain Injury
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • Other
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
  • Ways To Give
    • Giving to Research
    • How You Can Help
    • Events

Funded Grants

Back to results

Pathogenic Mechanism of C9orf72 haploinsufficiency in ALS/FTLD: a road to therapeutic discovery

Project Overview

In 2011, scientists discovered that hereditary mutation of a previously unstudied gene called C9ORF72 was the most prominent cause of both ALS and frontotemporal dementia (FTD). These mutations were found in both hereditary (familial) and non-hereditary (sporadic) forms of the disease and comprise about one third of all cases. Since that discovery, ALS researchers have aimed to understand the normal function of C9ORF72, determine how mutations in the gene can cause the disease and create animal and cellular models to study it. Previously, Dr. Janice Robertson published a landmark paper that demonstrated the existence of two different forms of C9ORF72 protein, including one that localized to the outer layer of the cell’s command centre called the nucleus. This was the first indication of what would become a breakthrough discovery by three teams independently showing that mutations in C9ORF72 disrupt the movements of critical substances into and out of the nucleus. In this Hudson project, the team led by Dr. Robertson will pursue a comprehensive understanding of the normal functions of C9ORF72 and provide a better determination of whether loss of these functions via mutation may cause or contribute to ALS.

Principal Investigator

Janice Robertson , University of Toronto

Partners and Donors

ALS Society of Canada

Project Ongoing

Pathogenic Mechanism of C9orf72 haploinsufficiency in ALS/FTLD: a road to therapeutic discovery

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Arthur J. Hudson Translational Team Grant

  • Province

    Ontario

  • Start Date

    2017

  • Total Grant Amount

    $1,647,800

  • Health Canada Contribution

    $823,900

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

+1 (514) 989-2989 info@braincanada.ca

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign Up

Territorial acknowledgement

The offices of Brain Canada Foundation are located on the traditional, ancestral territory of the Kanien'kehá:ka Peoples, a place which has long served as a site of meeting and exchange amongst nations. We honour and pay respect to elders past, present and emerging, and dedicate ourselves to moving forward in the spirit of partnership, collaboration, and reconciliation. In our work, we focus our efforts on the Truth and Reconciliation Commission’s Calls to Action, particularly those that pertain to improving health for Indigenous Peoples and that focus on advancing our own learning on Indigenous issues.

© 2023 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co